In our study, we retrospectively collected lymphoma tissues from DLBCL patients with refractory or relapsed (R/R) disease and complete remission (CR) and found that in the two groups, CENPF expression was higher in the R/R patients by real-time PCR and immunohistochemical staining, which demonstrated that CENPF overexpression may be associated with poor outcome in DLBCL patients. Here, CENPF is linked to lymphoma.